Lundbeck Raises Full-Year Guidance as Strategic Brands Grow 16 Percent

Lundbeck raised its 2026 guidance after nine-month revenue grew 13 percent at constant exchange rates, led by Vyepti.

Lundbeck reported nine-month 2026 revenue of DKK 20,191 million, up 13 percent at constant exchange rates, and on November 10 raised its full-year revenue growth guidance to 11 to 12 percent from 7 to 9 percent. [PRNewswire via TradingView — Lundbeck raises full-year guidance as 9M revenue grows 13 percent CER, led by Vyepti (November 10, 2026)]

The growth is concentrated where the company wants it. Revenue from strategic brands rose 16 percent at constant exchange rates to DKK 15,951 million, 79 percent of the total. EBITDA reached DKK 6,854 million, up 17 percent CER, and adjusted EBITDA DKK 7,026 million, up 19 percent. Earnings per share came in at DKK 4.11, up 30 percent in kroner terms, with adjusted EPS of DKK 5.42, up 25 percent. Third-quarter revenue alone was DKK 6,603 million, up 7 percent CER, and the company says all regions contributed to the nine-month growth. Alongside the revenue raise, adjusted EBITDA growth guidance moved to 15 to 19 percent CER, from 8 to 14 percent. [PRNewswire via TradingView — Lundbeck raises full-year guidance as 9M revenue grows 13 percent CER, led by Vyepti (November 10, 2026)]

Timing gives the raise its weight. A company lifting its full-year revenue band by four points at the bottom end in the second week of November, with most of the fourth quarter's orders visible, is making a statement that sits close to a report of fact. The release headline names the driver: Vyepti, the company's migraine treatment, leads the strategic brand portfolio that now produces nearly four-fifths of revenue. The concentration cuts both ways, as concentration does, but on the evidence of these nine months it is currently cutting in Lundbeck's favor. [PRNewswire via TradingView — Lundbeck raises full-year guidance as 9M revenue grows 13 percent CER, led by Vyepti (November 10, 2026)]